Literature DB >> 22749003

The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients.

Kenichi Matsuo1, Flavio G Rocha, Kaori Ito, Michael I D'Angelica, Peter J Allen, Yuman Fong, Ronald P Dematteo, Mithat Gonen, Itaru Endo, William R Jarnagin.   

Abstract

BACKGROUND: Complete resection of hilar cholangiocarcinoma (HCCA) is a critical determinant of long-term survival. This study validates a previously reported preoperative clinical T staging system for determining resectability of HCCA. STUDY
DESIGN: Consecutive patients with confirmed HCCA treated over an 18-year period were included. Patient demographics, preoperative imaging studies, resection type, margin status, lymph node status, histopathologic findings, morbidity, and outcomes were entered prospectively and analyzed retrospectively; changes in these variables over time were assessed. All patients were placed into 1 of 3 stages based on the extent of ductal involvement by tumor, portal vein compromise, or lobar atrophy.
RESULTS: From March 1991 through December 2008, 380 patients were evaluated. Eighty-five patients had unresectable disease; 295 patients underwent exploration with curative intent. One hundred fifty-seven patients underwent resection: 129 (82.2%) had a concomitant hepatic resection and 120 (76.4%) had an R0 resection. Of the 32 actual 5-year survivors (120 at risk), 30 patients (93.8%) had a concomitant hepatic resection. In patients who underwent an R0 resection, concomitant partial hepatectomy, well-differentiated histology, and negative lymph nodes were independent predictors of long-term survival. In the 376 patients whose disease could be staged, the preoperative clinical T staging system predicted resectability (p < 0.001), metastatic disease (p < 0.001), and R0 resection (p = 0.007).
CONCLUSIONS: The preoperative clinical T staging system of Blumgart, defined by the radial and longitudinal tumor extent, accurately predicts resectability of HCCA. The full outcomes benefit of resection is realized only if a concomitant partial hepatectomy is performed.
Copyright © 2012 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22749003     DOI: 10.1016/j.jamcollsurg.2012.05.025

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  69 in total

1.  The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection.

Authors:  Akira Iwaku; Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Hirokazu Nishino; Masato Matsushima; Hisao Tajiri
Journal:  Med Oncol       Date:  2013-12-06       Impact factor: 3.064

2.  Laparoscopic staging in hilar cholangiocarcinoma: Is it still justified?

Authors:  Fernando Rotellar; Fernando Pardo
Journal:  World J Gastrointest Oncol       Date:  2013-07-15

3.  Unresectable hilar cholangiocarcinoma treated with chemoradiotherapy: a 9-year survival case.

Authors:  Takeshi Sakata; Takahiro Yoshikawa; Takeo Nomi; Yasuko Matsuo; Naoki Kamitani; Daisuke Hokuto; Masayuki Sho
Journal:  Int Cancer Conf J       Date:  2020-09-19

4.  Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging.

Authors:  Jimme K Wiggers; Bas Groot Koerkamp; David van Klaveren; Robert J Coelen; C Yung Nio; Peter J Allen; Marc G Besselink; Olivier R Busch; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Thomas M van Gulik; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2018-04-06       Impact factor: 6.113

5.  The impact of cirrhosis and MELD score on postoperative morbidity and mortality among patients selected for liver resection.

Authors:  Victor M Zaydfudim; Florence E Turrentine; Mark E Smolkin; Todd B Bauer; Reid B Adams; Timothy L McMurry
Journal:  Am J Surg       Date:  2020-01-20       Impact factor: 2.565

6.  Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Daisuke Morioka; Ryutaro Mori; Yasuhiro Yabushita; Seigo Hiratani; Yohei Ota; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

7.  Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.

Authors:  Xu-Feng Zhang; Eliza W Beal; Jeffery Chakedis; Qinyu Chen; Yi Lv; Cecilia G Ethun; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

8.  American Joint Committee on Cancer staging for resected perihilar cholangiocarcinoma: a comparison of the 6th and 7th editions.

Authors:  Bas Groot Koerkamp; Jimme K Wiggers; Peter J Allen; Olivier R C Busch; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; Mithat Gonen; Dirk J Gouma; T Peter Kingham; Thomas M van Gulik; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2014-09-29       Impact factor: 3.647

Review 9.  The Surgical Management of Klatskin Tumours: Has Anything Changed in the Last Decade?

Authors:  Neil Bhardwaj; Giuseppe Garcea; Ashley R Dennison; Guy J Maddern
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

10.  Preoperative biliary drainage in perihilar cholangiocarcinoma: identifying patients who require percutaneous drainage after failed endoscopic drainage.

Authors:  Jimme K Wiggers; Bas Groot Koerkamp; Robert J Coelen; Erik A Rauws; Mark A Schattner; C Yung Nio; Karen T Brown; Mithat Gonen; Susan van Dieren; Krijn P van Lienden; Peter J Allen; Marc G H Besselink; Olivier R C Busch; Michael I D'Angelica; Robert P DeMatteo; Dirk J Gouma; T Peter Kingham; William R Jarnagin; Thomas M van Gulik
Journal:  Endoscopy       Date:  2015-09-18       Impact factor: 10.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.